TCGA-XF-AAN5-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 75.32851511
- os_event
- false
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.914 |
| 2 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.906 |
| 3 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.901 |
| 4 | SRR934802 | — | — | 0.898 |
| 5 | MNG766 | — | — | 0.885 |
| 6 | ERR2278855 | — | — | 0.881 |
| 7 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.881 |
| 8 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.881 |
| 9 | SRR934956 | — | — | 0.881 |
| 10 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |